Dengue: a continuing global threat

Dengue fever and dengue haemorrhagic fever are important arthropod-borne viral diseases. Each year, there are ∼50 million dengue infections and ∼500,000 individuals are hospitalized with dengue haemorrhagic fever, mainly in Southeast Asia, the Pacific and the Americas. Illness is produced by any of the four dengue virus serotypes. A global strategy aimed at increasing the capacity for surveillance and outbreak response, changing behaviours and reducing the disease burden using integrated vector management in conjunction with early and accurate diagnosis has been advocated. Antiviral drugs and vaccines that are currently under development could also make an important contribution to dengue control in the future.

[1]  F. Guirakhoo,et al.  Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.

[2]  A. Nisalak,et al.  IgM capture ELISA for detection of IgM antibodies to dengue virus: comparison of 2 formats using hemagglutinins and cell culture derived antigens. , 1992, The Southeast Asian journal of tropical medicine and public health.

[3]  R. Lanciotti,et al.  Serotype-Specific Detection of Dengue Viruses in a Fourplex Real-Time Reverse Transcriptase PCR Assay , 2005, Journal of Clinical Microbiology.

[4]  M. Guzmán,et al.  Diagnosis of Dengue Virus Infection by Detection of Specific Immunoglobulin M (IgM) and IgA Antibodies in Serum and Saliva , 2003, Clinical Diagnostic Laboratory Immunology.

[5]  M. Guzmán,et al.  [Standardization of immunohistochemical techniques for detecting dengue virus antigens in paraffin-embedded tissues]. , 1997, Revista Cubana de Medicina Tropical.

[6]  T. Jelínek,et al.  Dengue fever in international travelers. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  K. Porter,et al.  A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. , 2006, Virology.

[8]  M. St. Claire,et al.  Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention , 2007, Proceedings of the National Academy of Sciences.

[9]  K. Johnson.  An Update. , 1984, Journal of food protection.

[10]  I. Gartside,et al.  Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? , 2000, Clinical science.

[11]  Denise A. Martin,et al.  Immunoassay Targeting Nonstructural Protein 5 To Differentiate West Nile Virus Infection from Dengue and St. Louis Encephalitis Virus Infections and from Flavivirus Vaccination , 2003, Journal of Clinical Microbiology.

[12]  A. Barrett,et al.  Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses. , 2008, Viral immunology.

[13]  M. Guzmán,et al.  Race: a risk factor for dengue hemorrhagic fever , 2006, Archives of Virology.

[14]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[15]  P. Marianneau,et al.  Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. , 1999, Human pathology.

[16]  Manuel Ochoa,et al.  Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomised trials , 2006, British medical journal.

[17]  N. White,et al.  Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? , 2001, The Journal of infectious diseases.

[18]  C. King,et al.  Flow Cytometry Compared with Indirect Immunofluorescence for Rapid Detection of Dengue Virus Type 1 after Amplification in Tissue Culture , 2001, Journal of Clinical Microbiology.

[19]  S. Kalayanarooj,et al.  Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. , 2007, The Journal of general virology.

[20]  J. Hombach.  Vaccines against dengue: a review of current candidate vaccines at advanced development stages. , 2007, Revista panamericana de salud publica = Pan American journal of public health.

[21]  N. White,et al.  Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. , 2002, The American journal of tropical medicine and hygiene.

[22]  M. Guzmán,et al.  Apoptosis in tissues from fatal dengue shock syndrome. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[23]  S. Higgs,et al.  Aedes aegypti salivary gland extracts modulate anti-viral and TH1/TH2 cytokine responses to sindbis virus infection. , 2004, Viral immunology.

[24]  M. Guzmán,et al.  Dengue: an update. , 2002, The Lancet. Infectious diseases.

[25]  M. Guzmán,et al.  Fatal dengue hemorrhagic fever in Cuba, 1997. , 1999, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[26]  C. Romero-Vivas,et al.  Altered Enzyme-Linked Immunosorbent Assay Immunoglobulin M (IgM)/IgG Optical Density Ratios Can Correctly Classify All Primary or Secondary Dengue Virus Infections 1 Day after the Onset of Symptoms, when All of the Viruses Can Be Isolated , 2006, Clinical and Vaccine Immunology.

[27]  Tao Dong,et al.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.

[28]  M. C. Williams,et al.  Dengue in the Caribbean: virus isolation in a mosquito (Aedes pseudoscutellaris) cell line. , 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[29]  J. Bisset,et al.  LEVELS OF INSECTICIDE RESISTANCE AND RESISTANCE MECHANISMS IN AEDES AEGYPTI FROM SOME LATIN AMERICAN COUNTRIES , 2007, Journal of the American Mosquito Control Association.

[30]  A. Nisalak,et al.  Comparison of four reverse transcription-polymerase chain reaction procedures for the detection of dengue virus in clinical specimens. , 2002, Journal of virological methods.

[31]  S. Halstead,et al.  Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. , 2001, The American journal of tropical medicine and hygiene.

[32]  S. Halstead,et al.  Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. , 2005, Vaccine.

[33]  K. Yuen,et al.  Serotype 1-Specific Monoclonal Antibody-Based Antigen Capture Immunoassay for Detection of Circulating Nonstructural Protein NS1: Implications for Early Diagnosis and Serotyping of Dengue Virus Infections , 2006, Journal of Clinical Microbiology.

[34]  D. Gubler,et al.  Impact of dengue/dengue hemorrhagic fever on the developing world. , 1999, Advances in virus research.

[35]  Tyen‐Po Chen,et al.  Clinical characteristics of dengue and dengue hemorrhagic fever in a medical center of southern Taiwan during the 2002 epidemic. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[36]  C. Villarreal-Garza,et al.  HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. , 2002, Human immunology.

[37]  S. Watowich,et al.  Evolutionary Relationships of Endemic/Epidemic and Sylvatic Dengue Viruses , 2000, Journal of Virology.

[38]  E. Torres.  La prevención de la mortalidad por dengue: un espacio y un reto para la atención primaria de salud , 2006 .

[39]  M. Guzmán,et al.  A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. , 2006, Vaccine.

[40]  M. Mulla,et al.  Mosquito burden and impact on the poor: measures and costs for personal protection in some communities in Thailand. , 2001, Journal of the American Mosquito Control Association.

[41]  D. Gubler,et al.  Dengue and dengue haemorrhagic fever , 1998, The Lancet.

[42]  I. Kurane,et al.  Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[43]  S. Halstead.  In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. , 1979, The Journal of infectious diseases.

[44]  S. Nimmannitya,et al.  Clinical spectrum and management of dengue haemorrhagic fever. , 1987, The Southeast Asian journal of tropical medicine and public health.

[45]  D. Gubler,et al.  The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? , 2004, Comparative immunology, microbiology and infectious diseases.

[46]  J. Farrar,et al.  Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. , 2007, The Journal of infectious diseases.

[47]  Chwan-Chuen King,et al.  Detection of Dengue Viral RNA Using a Nucleic Acid Sequence-Based Amplification Assay , 2001, Journal of Clinical Microbiology.

[48]  S. Halstead,et al.  Original antigenic sin in dengue. , 1983, The American journal of tropical medicine and hygiene.

[49]  S. Halstead,et al.  Do escape mutants explain rapid increases in dengue casefatality rates within epidemics? , 2000, The Lancet.

[50]  Laura D. Kramer,et al.  Typing of Dengue Viruses in Clinical Specimens and Mosquitoes by Single-Tube Multiplex Reverse Transcriptase PCR , 1998, Journal of Clinical Microbiology.

[51]  S. Halstead,et al.  Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization , 1985, Journal of clinical microbiology.

[52]  Cameron P Simmons,et al.  The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. , 2010, Cell host & microbe.

[53]  Ting-Hsiang Lin,et al.  Comparison of Capture Immunoglobulin M (IgM) and IgG Enzyme-Linked Immunosorbent Assay (ELISA) and Nonstructural Protein NS1 Serotype-Specific IgG ELISA for Differentiation of Primary and Secondary Dengue Virus Infections , 2003, Clinical Diagnostic Laboratory Immunology.

[54]  M. Cardosa,et al.  Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. , 2002, BMC Microbiology.

[55]  Rosanna W. Peeling,et al.  Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests , 2009, Emerging infectious diseases.

[56]  K. Wong,et al.  Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. , 2004, The Journal of infectious diseases.

[57]  B. Murphy,et al.  Prospects for a dengue virus vaccine , 2007, Nature Reviews Microbiology.

[58]  M. Guzmán,et al.  Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[59]  T. Jelínek,et al.  Dengue Antibody Prevalence in German Travelers , 2005, Emerging Infectious Diseases.

[60]  Susana Vázquez,et al.  Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. , 2006, The American journal of tropical medicine and hygiene.

[61]  S. Devi,et al.  Rapid detection, serotyping and quantitation of dengue viruses by TaqMan real-time one-step RT-PCR. , 2006, Journal of virological methods.

[62]  V. S. Nam,et al.  National progress in dengue vector control in Vietnam: survey for Mesocyclops (Copepoda), Micronecta (Corixidae), and fish as biological control agents. , 2000, The American journal of tropical medicine and hygiene.

[63]  J. Morgan,et al.  Pyrethroid and DDT cross‐resistance in Aedes aegypti is correlated with novel mutations in the voltage‐gated sodium channel gene , 2003, Medical and veterinary entomology.

[64]  Angel Balmaseda,et al.  Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. , 2005, The American journal of tropical medicine and hygiene.

[65]  S. Halstead,et al.  Epidemiologic studies on Dengue in Santiago de Cuba, 1997. , 2000, American journal of epidemiology.

[66]  C. Peters,et al.  Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. , 1991, The American journal of tropical medicine and hygiene.

[67]  A. Kroeger,et al.  Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever , 2006, Tropical medicine & international health : TM & IH.

[68]  L. Rosen,et al.  Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. , 1999, The American journal of tropical medicine and hygiene.

[69]  Anavaj Sakuntabhai,et al.  A variant in the CD209 promoter is associated with severity of dengue disease , 2005, Nature Genetics.

[70]  D. Focks.  Multicountry study of Aedes aegypti pupal productivity survey methodology : Findings and recommendations , 2006 .

[71]  M. Guzmán,et al.  Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. , 1990, The American journal of tropical medicine and hygiene.

[72]  L. Lloyd,et al.  Planning social mobilization and communication for dengue fever prevention and control: a step-by-step guide. , 2004 .

[73]  Z. Layrisse,et al.  TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. , 2004, Tissue antigens.

[74]  G. Kuno,et al.  An ELISA procedure for the diagnosis of dengue infections. , 1991, Journal of virological methods.

[75]  A. Nisalak,et al.  The comparative accuracy of 8 commercial rapid immunochromatographic assays for the diagnosis of acute dengue virus infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  A. Nisalak,et al.  HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. , 2002, Tissue antigens.

[77]  S. Nimmannitya,et al.  Nutritional status of children with dengue hemorrhagic fever. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  J. Gruenberg,et al.  The Secreted Form of Dengue Virus Nonstructural Protein NS1 Is Endocytosed by Hepatocytes and Accumulates in Late Endosomes: Implications for Viral Infectivity , 2005, Journal of Virology.

[79]  J. Lang,et al.  A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.

[80]  A. Nisalak,et al.  Dengue virus identification by the plaque reduction neutralization test. , 1967, Journal of immunology.

[81]  R. Lanciotti,et al.  Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction , 1992, Journal of clinical microbiology.

[82]  A. Barrett,et al.  Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. , 2007, Vaccine.

[83]  M. Guzmán,et al.  Dengue diagnosis, advances and challenges. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[84]  R. Karron,et al.  rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers , 2005 .

[85]  HUmAN SERvICES,et al.  International Health Regulations. , 1971, British medical journal.

[86]  M. Seguin,et al.  Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. , 1983, The American journal of tropical medicine and hygiene.

[87]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[88]  D. Gubler,et al.  Dengue and dengue hemorrhagic fever in the Americas. , 1987, Puerto Rico health sciences journal.

[89]  M. V. Cabrera,et al.  IgM antibodies to dengue virus in dried blood on filter paper. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[90]  V. S. Nam,et al.  Control of aedes vectors of dengue in three provinces of Vietnam by use of Mesocyclops (Copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance. , 2002, The American journal of tropical medicine and hygiene.

[91]  R. Rico-Hesse.  Microevolution and virulence of dengue viruses. , 2003, Advances in virus research.

[92]  Analysis of recombinant dengue virus polypeptides for dengue diagnosis and evaluation of the humoral immune response. , 2004, The American journal of tropical medicine and hygiene.

[93]  Ira B Schwartz,et al.  Dynamic effects of antibody-dependent enhancement on the fitness of viruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Alan L Rothman,et al.  Dengue: defining protective versus pathologic immunity. , 2004, The Journal of clinical investigation.

[95]  D. Gubler,et al.  Dengue and dengue hemorrhagic fever. , 2014 .

[96]  G. Chang,et al.  Development of Real-Time Reverse Transcriptase PCR Assays To Detect and Serotype Dengue Viruses , 2006, Journal of Clinical Microbiology.

[97]  B. Murphy,et al.  A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys , 2003, Journal of Virology.

[98]  M. Guzmán,et al.  Detección de IgM contra el virus del dengue en sangre entera absorbida en papel de filtro , 1998 .

[99]  T. Osawa,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010 .

[100]  P. S. Thangaratham,et al.  Indian perspective on the need for new case definitions of severe dengue. , 2007, The Lancet. Infectious diseases.

[101]  SB Halstead,et al.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.

[102]  A. Paulen.  A time for reassessment. , 1986, Cancer nursing.

[103]  M. Blettner,et al.  Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. , 2006, The Journal of infectious diseases.

[104]  A. Nisalak,et al.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. , 2009, The American journal of tropical medicine and hygiene.

[105]  M. Saeed,et al.  Dengue and Dengue Hemorrhagic Fever , 2015 .

[106]  P. Young,et al.  An Antigen Capture Enzyme-Linked Immunosorbent Assay Reveals High Levels of the Dengue Virus Protein NS1 in the Sera of Infected Patients , 2000, Journal of Clinical Microbiology.

[107]  B. McKinney,et al.  Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. , 2009, The American journal of tropical medicine and hygiene.

[108]  S. Halstead,et al.  Dengue virus-mosquito interactions. , 2008, Annual review of entomology.

[109]  M. Guzmán,et al.  Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. , 2006, Viral immunology.

[110]  M. Guzmán,et al.  Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[111]  D. Vaughn,et al.  Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. , 2003, The American journal of tropical medicine and hygiene.

[112]  J. Mascola,et al.  Human skin Langerhans cells are targets of dengue virus infection , 2000, Nature Medicine.

[113]  R. Bos.  Global Strategic Framework for Integrated Vector Management , 2004 .

[114]  S. Halstead,et al.  Effect of age on outcome of secondary dengue 2 infections. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[115]  A. Nisalak,et al.  Blood group AB is associated with increased risk for severe dengue disease in secondary infections. , 2007, The Journal of infectious diseases.

[116]  K. Morita,et al.  Rapid identification of dengue virus serotypes by using polymerase chain reaction , 1991, Journal of clinical microbiology.

[117]  P. Malasit.  Complement and dengue haemorrhagic fever/shock syndrome. , 1987, The Southeast Asian journal of tropical medicine and public health.

[118]  M. Guzmán,et al.  Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[119]  D. Pérez,et al.  What do community-based dengue control programmes achieve? A systematic review of published evaluations. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[120]  A. Nisalak,et al.  An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. , 1989, The American journal of tropical medicine and hygiene.

[121]  Jacqueline L Deen,et al.  The WHO dengue classification and case definitions: time for a reassessment , 2006, The Lancet.

[122]  S. Halstead,et al.  Virus evolution during a severe dengue epidemic in Cuba, 1997. , 2005, Virology.

[123]  Eli Schwartz,et al.  Dengue in travelers. , 2005, The New England journal of medicine.

[124]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.

[125]  B. A. Harrison,et al.  Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. , 1987, The American journal of tropical medicine and hygiene.

[126]  A. di Caro,et al.  Recent expansion of dengue virus serotype 3 in West Africa. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[127]  Susana Vázquez,et al.  Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. , 2002, Revista panamericana de salud publica = Pan American journal of public health.

[128]  A. Nisalak,et al.  Prospective Study To Determine Accuracy of Rapid Serological Assays for Diagnosis of Acute Dengue Virus Infection in Laos , 2007, Clinical and Vaccine Immunology.

[129]  M. Cetron,et al.  Spectrum of disease and relation to place of exposure among ill returned travelers. , 2006, The New England journal of medicine.

[130]  Ting-Hsiang Lin,et al.  Potential Application of Nonstructural Protein NS1 Serotype-Specific Immunoglobulin G Enzyme-Linked Immunosorbent Assay in the Seroepidemiologic Study of Dengue Virus Infection: Correlation of Results with Those of the Plaque Reduction Neutralization Test , 2002, Journal of Clinical Microbiology.

[131]  J. Rigau-Pérez,et al.  Severe dengue: the need for new case definitions. , 2006, The Lancet. Infectious diseases.

[132]  Yee‐Shin Lin,et al.  Autoimmune pathogenesis in dengue virus infection. , 2006, Viral immunology.

[133]  M. Guzmán,et al.  ELISA de inhibición: Su utilidad para clasificar un caso de dengue , 1997 .

[134]  N. Karabatsos,et al.  Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. , 1989, The Journal of general virology.